Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis
Oncology Research · 2025 · 33 (9) · 2529-2547
DOI: 10.32604/or.2025.065029 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oncology Research, 2025. Verfasst von Xizhou Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatmen…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunoconjugates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Breast Center, Cancer Hospital of Shantou University Medical College, Guangdong Provincial Key Laboratory of Breast Cancer Diagnosis and Treatment, Shantou, 515031, China.
- Department of Oncology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, China.
Zitieren
APA
Zhang, X., Zhang, Z., Lin, J., Yi, J., Zou, X., Feng, J., Huang, G., Chen, B., Long, J., Wu, F., Ye, F., & Wu, H. (2025). Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis. Oncology Research, 33(9), 2529-2547. https://doi.org/10.32604/or.2025.065029
Vancouver
Zhang X, Zhang Z, Lin J, Yi J, Zou X, Feng J, et al. Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis. Oncology Research. 2025;33(9):2529-2547. doi:10.32604/or.2025.065029
BibTeX
@article{Zhang2025,
author = {Zhang, Xizhou and Zhang, Zetao and Lin, Jianguang and Yi, Jiarong and Zou, Xuxiazi and Feng, Jikun and Huang, Guangsheng and Chen, Bingfeng and Long, Junxi and Wu, Fengjia and Ye, Feng and Wu, Haoming},
title = {Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis},
journal = {Oncology Research},
year = {2025},
volume = {33},
number = {9},
pages = {2529--2547},
doi = {10.32604/or.2025.065029}
}
EUVIMED